PRESS RELEASE

Wednesday, August 7, 2002

Company Press Release

SOURCE: BioMedicines, Inc.

BioMedicines, Inc. Completes Phase 1b Enrollment with Biomed 101

Emeryville, CA - August 7, 2002 - BioMedicines, Inc. today announced that it has completed enrollment in a phase 1b clinical trial of its drug Biomed 101 in patients also receiving therapy with interleukin-2 for treatment of metatstatic renal cell cancer. BioMedicines is developing Biomed 101 to mitigate the dose-limiting toxicity currently associated interleukin-2 therapy.

"We have shown in this dose-escalation study that patients treated with Biomed 101 are able to better tolerate interleukin-2", said Peter Langecker, M.D., Ph.D., Vice President of Clinical Affairs. "We are also encouraged that the patients who received increased numbers of interleukin-2 doses experienced fewer serious side effects."

Biomed 101 is an experimental drug that binds to the leukotriene B4 receptor. BioMedicines has exclusive worldwide commercial rights to this drug and has recently received patents covering its discoveries. Commenting on the Biomed 101 program to date, Curtis Scribner, M.D. Vice President of Regulatory Affairs said, "We have met with the FDA this year regarding further development of Biomed 101 and believe the results from this study form a strong for basis for advancing this program to the next phase of development—a double-blind placebo-controlled study."

BioMedicines, Inc., a privately held pharmaceutical company, has three products in clinical testing at phase 1b, 2, and 3 in the fields of cancer and infectious diseases. BioMedicines specializes in redirecting the development of drugs to new and more valuable indications. The company has current development and/or commercialization agreements with ALZA, Boehringer Ingelheim, Schering AG, and the G.D. Searle subsidiary of Pharmacia. BioMedicines is headquartered in Emeryville, California. More information about the company is available at www.biomedicinesinc.com.

| Back |